LeMaitre Vascular (NASDAQ:LMAT) Shares Gap Down – Should You Sell?

LeMaitre Vascular, Inc. (NASDAQ:LMAT) gapped down prior to trading on Monday . The stock had previously closed at $100.69, but opened at $91.12. LeMaitre Vascular shares last traded at $92.96, with a volume of 68,968 shares.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday. Oppenheimer reaffirmed an “outperform” rating and set a $93.00 price target (up previously from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Cantor Fitzgerald initiated coverage on LeMaitre Vascular in a report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price objective on the stock. JMP Securities raised their price objective on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 20th. Finally, Barrington Research upped their target price on LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $94.57.

LeMaitre Vascular Trading Down 7.0 %

The firm has a market cap of $2.11 billion, a price-to-earnings ratio of 51.20, a PEG ratio of 2.47 and a beta of 0.93. The company has a fifty day moving average price of $97.65 and a 200-day moving average price of $89.62.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The company had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. LeMaitre Vascular’s revenue for the quarter was up 15.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.33 earnings per share. As a group, research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, December 5th. Investors of record on Thursday, November 21st were issued a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.68%. The ex-dividend date of this dividend was Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 34.97%.

Insider Buying and Selling at LeMaitre Vascular

In other news, Director Bridget A. Ross sold 3,750 shares of the firm’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $101.47, for a total transaction of $380,512.50. Following the sale, the director now directly owns 2,278 shares in the company, valued at $231,148.66. This trade represents a 62.21 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 10.79% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On LeMaitre Vascular

A number of large investors have recently bought and sold shares of LMAT. NBC Securities Inc. increased its position in shares of LeMaitre Vascular by 73.2% in the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 183 shares in the last quarter. West Oak Capital LLC acquired a new stake in LeMaitre Vascular in the 2nd quarter valued at $58,000. USA Financial Formulas purchased a new stake in LeMaitre Vascular in the 3rd quarter worth $60,000. nVerses Capital LLC raised its position in LeMaitre Vascular by 33.3% during the second quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock worth $66,000 after acquiring an additional 200 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in LeMaitre Vascular by 34.3% during the third quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock valued at $68,000 after purchasing an additional 188 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.